Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XTSBP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AXL-733-MMAE
|
|||||
| Synonyms |
AXL 733 MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 4 Indication(s)
Cervical cancer [ICD11:2C77]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Melanoma [ICD11:2C30]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
AXL-733
|
Antibody Info | ||||
| Antigen Name |
Tyrosine-protein kinase receptor UFO (AXL)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 28.2
|
%
|
LCLC-103H cells
|
Lung large cell carcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 57.70% (Day 14) | Positive AXL expression (AXL+++/++) | ||
| Method Description |
The anti-tumor activity of ADCs were determined in the pancreas cancer patient-derived xenograft (PDX) model PAXF1657. Before treatment,mice were divided into groups of 68 mice each,with equal tumor size distribution (average and variance). ADC is administered at a dose of 2.00 mg/kg in a single dose.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PAXF1657) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.30% (Day 14) | Positive AXL expression (AXL+++/++) | ||
| Method Description |
The anti-tumor activity of ADCs were determined in the pancreas cancer patient-derived xenograft (PDX) model PAXF1657. Before treatment,mice were divided into groups of 68 mice each,with equal tumor size distribution (average and variance). ADC is administered at a dose of 4.00 mg/kg in a single dose.
|
||||
| In Vivo Model | Pancreatic cancer PDX model (PDX: PAXF1657) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 28.20% (Day 18) | Positive AXL expression (AXL+++/++) | ||
| Method Description |
In the LCLC-103H xenograft model,therapeutic treatment with a single dose of 1 mg/kg in anti-tumor activity in the AXL-ADC panel.
|
||||
| In Vivo Model | Lung cancer CDX model | ||||
| In Vitro Model | Lung large cell carcinoma | LCLC-103H cells | CVCL_1375 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.